Welcome to our dedicated page for Innovate SEC filings (Ticker: VATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The INNOVATE Corp. (NYSE: VATE) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Form 8-K current reports and other key documents. These filings provide detail on INNOVATE’s portfolio across its Infrastructure, Life Sciences and Spectrum segments and on its capital structure.
Form 8-K current reports for INNOVATE frequently announce quarterly financial results, segment performance and significant events at portfolio companies. Examples include earnings releases for the second and third quarters, updates on DBM Global Inc. cash dividends, and press releases about MediBeacon’s regulatory approvals in the United States and China and R2 Technologies’ growth in Glacial Skin CryoAesthetics platforms.
INNOVATE also uses Form 8-K to disclose financing and refinancing transactions. Recent filings describe exchanges of senior secured notes for new notes with extended maturities, amendments to convertible notes, extensions of the company’s revolving credit agreement, changes to a subordinated secured promissory note with Continental General Insurance Company and extensions of Spectrum and R2 Technologies notes. These documents outline the terms of the new instruments, maturity dates, interest rates and related conditions.
Through this page, users can track how INNOVATE reports revenue by segment, net income or loss by segment and Adjusted EBITDA in its earnings-related filings, as well as how it documents material events such as regulatory approvals and strategic processes linked to debt covenants. Stock Titan’s interface surfaces new filings as they appear on EDGAR and offers AI-powered summaries to help interpret lengthy disclosures, from note exchange terms to segment-level commentary.
Investors researching VATE can review Forms 8-K and related exhibits here to understand INNOVATE’s reporting practices, segment updates, debt profile and the regulatory record of its portfolio companies.
INNOVATE Corp. is holding its 2026 annual stockholder meeting virtually on June 11, 2026, where common and preferred holders will vote together on four key proposals.
Stockholders will elect four directors, cast an advisory vote on executive pay, approve an increase in shares available under the Second Amended and Restated 2014 Omnibus Equity Award Plan, and ratify BDO USA, P.C. as auditor. The board recommends voting FOR all items.
The proxy also highlights 2025 business results, including DBM Global revenue of $1,210.3 million, up 12.9% year-over-year, MediBeacon kidney-function product approvals in the U.S. and China, and record revenue at R2 Technologies. Governance features include a separate independent chair and CEO, majority voting for uncontested director elections, performance-based compensation, and minimum one-year vesting on equity awards. In 2025 the interim CEO’s reported pay was $1.84 million and the CFO’s was $0.94 million, combining salary, equity and incentives aligned with company performance.
INNOVATE Corp. reported that its portfolio company DBM Global Inc. (DBMG), an operating subsidiary providing integrated steel construction services, has declared a cash dividend of approximately $3 million, or $0.78 per share.
The dividend is scheduled to be paid on April 28, 2026 to DBMG stockholders of record as of the close of business on April 13, 2026. As DBMG’s largest stockholder, INNOVATE expects to receive approximately $2.7 million of the total dividend. The company clarified that INNOVATE’s own stockholders will not receive this cash dividend; it is paid only to DBMG’s stockholders.
INNOVATE Corp. reports that its equity method investment MediBeacon has received European Union CE Mark certification under the EU Medical Device Regulation 2017/745 for its TGFR Monitor and TGFR Reusable Sensor. This confirms the devices meet EU safety, quality, and performance standards.
The TGFR System combines the Monitor, Reusable Sensor, Disposable Ring, and Lumitrace (relmapirazin) injection to assess kidney function by measuring fluorescent tracer clearance through the skin, providing a transdermal measure of glomerular filtration rate. Lumitrace injection is approved in the U.S. and China, with an EU submission pending, and the system is already approved for human use by the U.S. FDA and China NMPA.
INNOVATE Corp. is a diversified holding company with three main platforms: Infrastructure (DBM Global), Life Sciences (Pansend) and Spectrum (HC2 Broadcasting), plus smaller investments. The report notes substantial doubt about the company’s ability to continue as a going concern, driven by high leverage and restrictive covenants.
New milestone covenants tied to 2027 senior notes and other debt have forced sales processes for the Infrastructure and Spectrum segments. DBM Global generated $1,210.3 million of 2025 revenue with a $1,723.9 million backlog and a large project pipeline, but must be marketed for sale after missing required asset-sale milestones.
Pansend controls R2 Technologies and Genovel, and holds a 44.6% stake in MediBeacon, whose TGFR kidney function system received FDA and China approvals in 2025. HC2 Broadcasting operates 257 TV stations across 112 U.S. and Puerto Rico markets using a cloud-based IP backbone. The company also discloses significant holding-company debt and reliance on subsidiary distributions for liquidity.
INNOVATE Corp. reported strong fourth-quarter 2025 growth but remained unprofitable. Revenue for the quarter rose to $382.7 million, up 61.7% from $236.6 million, driven mainly by the Infrastructure segment. Full-year revenue reached $1,246.0 million, up 12.5% from $1,107.1 million.
Quarterly net loss attributable to common and participating preferred stockholders narrowed to $7.8 million (loss of $0.58 per share) from $16.9 million (loss of $1.29 per share), though the full-year loss widened to $64.0 million from $35.8 million. Total Adjusted EBITDA improved in the quarter to $24.5 million from $15.0 million, but declined for the year to $67.2 million from $71.3 million.
Infrastructure revenue climbed to $373.9 million in Q4, with adjusted backlog of $1.8 billion, up from $1.1 billion a year earlier. In Life Sciences, MediBeacon received U.S. FDA approval for its next-generation TGFR system, while R2 delivered full-year 2025 revenue of $12.5 million, up 27.6%. Spectrum faced softer advertising and lower revenue, but cited favorable FCC rulings, new network launches and successful datacasting trials as 2026 growth drivers. Cash and cash equivalents rose to $112.1 million, while total debt stood at $661.7 million and stockholders’ deficit was $226.2 million.
INNOVATE Corp. Chief Financial Officer Michael J. Sena reported routine tax-related share dispositions. Over three days, a total of 7,911 shares of common stock were withheld by the company to cover taxes tied to vesting of restricted stock, at prices between $4.22 and $4.35 per share. After these non-market tax-withholding transactions, he directly holds 115,982 common shares.
INNOVATE Corp. reported that MediBeacon, in which it holds a 44.7% equity interest, had a peer-reviewed article on its transdermal GFR (tGFR) measurement recognized as one of five 2025 Editors’ Choice articles by the Journal of the American Society of Nephrology.
The featured work describes MediBeacon’s TGFR System, which uses the Lumitrace (relmapirazin) fluorescent tracer and a wearable sensor to measure kidney function through the skin at the point of care. The article was featured on the journal’s August 2025 cover.
The TGFR System is approved for human use, and commercialization through centers of excellence in select academic medical centers began in January 2026, initially focusing on heart failure monitoring, transplant evaluation and oncology drug dosing.
INNOVATE Corp. filed a current report to note that one of its portfolio companies, referred to as Global, plans to pay a cash dividend. The company disclosed this by issuing a press release titled “INNOVATE’s Portfolio Company Global to Pay Cash Dividend,” which is included as an exhibit.
The press release is attached as Exhibit 99.1 and is furnished rather than filed, meaning it is not automatically incorporated into other securities law filings. The report also includes the cover page interactive data file as Exhibit 104.
INNOVATE Corp. reported that on December 16, 2025 it issued a press release titled “MediBeacon® Next Generation TGFRTM System Receives FDA Approval,” announcing that this MediBeacon system has received FDA approval. This highlights a notable regulatory milestone for that product.
The company is sharing the news with investors through the press release, which is attached as Exhibit 99.1 and is not deemed filed for purposes of Section 18 of the Exchange Act or automatically incorporated into Securities Act filings. INNOVATE’s common stock, par value $0.001 per share, is listed on the New York Stock Exchange under the symbol VATE.
Whitefort Capital Management, with David Salanic and Joseph Kaplan, filed Amendment No. 1 to Schedule 13G reporting 7.8% beneficial ownership of INNOVATE Corp. (VATE), totaling 1,059,897 shares as of September 30, 2025.
The position comprises 743,000 shares plus $13,409,255 principal amount of the issuer’s 9.5% convertible senior notes due 2027, currently convertible into 316,897 shares. The percentage is based on 13,336,149 shares outstanding as of August 1, 2025. The reporting persons disclose shared voting and dispositive power over the reported shares and certify the securities were not acquired to change or influence control.